Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v6-EN
Language English English
Date Updated 2020-11-28 2020-11-26
Drug Identification Number 02247938 02247938
Brand name VASOPRESSIN INJECTION USP VASOPRESSIN INJECTION USP
Common or Proper name VASOPRESSIN INJECTION USP VASOPRESSIN INJECTION USP
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients VASOPRESSIN VASOPRESSIN
Strength(s) 20UNIT 20UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS
Packaging size 20IU/ML 5ML LIVI CA 20IU/ML 5ML LIVI CA
ATC code H01BA H01BA
ATC description POSTERIOR PITUITARY LOBE HORMONES POSTERIOR PITUITARY LOBE HORMONES
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2020-10-30 2020-10-30
Actual start date 2020-10-30 2020-10-30
Estimated end date 2020-12-31
Actual end date 2020-11-27 2020-11-27
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments